In-vitro and Companion Diagnostics Industry - 2010 Yearbook

Document Sample
In-vitro and Companion Diagnostics Industry - 2010 Yearbook Powered By Docstoc
					             In-vitro and Companion Diagnostics Industry - 2010
                                 Yearbook
 Reference Code: GBIHC064MR                                                                                                       Publication Date: January 2011


                                     Global In-Vitro Diagnostics (IVD) and Companion Diagnostics (CDx) Market Set To Boom In
                                     The Next Seven Years
Global IVD and CD                    The global IVD and CDx market was valued at $30.4 billion in 2009 and is forecast to grow to $42.2
market was valued at                 billion by 2016 at the rate of 4.8% over the next seven years. Immuno chemistry and Clinical
$30.4 billion in 2009.               chemistry markets will be the largest IVD categories, accounting for nearly 60% of the total
Reduction of costs will              revenues. These markets are expected to grow at 5.2% and 4.1% CAGR (Compounded Annual
remain the main strategy             Growth Rate) between 2009 and 2016, to reach $15,477.4m and $9,506.7m respectively. The
of diagnostic companies.             genetic testing market will be the fastest growing market, at a CAGR of 6% during 2009–2016, to
Drug and diagnostic co-              become an over the billion dollar market. The global IVD and CDx market will be driven by new
development is being                 technological advancements, a shift towards more complex immunochemistry tests to Point of Care
seen as one of the most              (POC), and the adoption of cost cutting measures such as increased automation and self testing.
promising strategies to              Major technological advancements such as next generation DNA sequencing, molecular imaging,
reduce costs                         and microfluidics-based diagnostic devices are expected to drive growth in categories such as
                                     immunochemistry and genetic testing.

                                       IVD Market, Global, Revenue ($m), 2009-2016

                                                          45,000


                                                          40,000


                                                          35,000


                                                          30,000
                                           Revenue ($m)




                                                          25,000


                                                          20,000


                                                          15,000


                                                          10,000


                                                           5,000


                                                              0
                                                                                  2009                             2012                          2016

                                                                   Immuno Chemistry       Clinical Chemistry         Infectious Immunology   Hematology
                                                                   Microbiology Culture   Histology And Cytology     Genetic Testing

                                       Source: GBI Research, Company Annual Reports, KOL Interviews




In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                                                       GBIHC064MR / Published JAN 2011
                                                                                                                                                          Page 1
                                                                                          © GBI Research. This is a licensed product and is not to be photocopied
                                     Need to Control Costs at Laboratories to Drive Adoption of New Processes and Instruments
                                     Cost reduction has become the primary theme of healthcare reforms globally. To survive and
                                     succeed in these challenging conditions, it is imperative for laboratories to look for ways to adapt
                                     and implement new strategies to help them save on costs. In today’s competitive environment,
                                     revenues per test are continually falling, requiring testing centers to increase their productivity for
                                     survival. The paradigm shift towards improved quality, error free services, and the need to ensure
                                     patient satisfaction to retain their allegiance has prompted laboratories to adopt novel technologies
                                     such as automation and point of care, in order to reduce their expenses. The acceptance of new
                                     technologies is expected to drastically improve among those who are currently reluctant to invest to
                                     achieve long term cost reduction goals. Companion diagnostics, in particular, hold great potential to
                                     reduce healthcare costs.
                                     Roche, Siemens, Abbott and Beckman Coulter Dominate the Global IVD Market

                                       IVD Market, Global, Company Share (%), 2009

                                                                                      F. Hoffmann-La Roche
                                                                                               Ltd.
                                                                                               12%



                                                                                                              Siemens Healthcare
                                                                                                                    10%




                                                                                                                 Abbott Laboratories
                                                                                                                         8%




                                                           Others
                                                            70%



                                       Source: GBI Research, Company Annual Reports, Investor Presentations, KOL Interviews




                                     F. Hoffmann-La Roche Ltd (Roche), Siemens Medical Solutions (Siemens), Abbott Laboratories
                                     (Abbott) and Beckman Coulter were the leading companies in the global IVD market in 2009.
                                     These top four companies accounted for 36% of the total market share. Roche was the market
                                     leader and accounted for 12% of the market in 2009. Siemens, Abbott, and Beckman Coulter
                                     accounted for 10%, 8%, and 6% respectively. The global market for IVD is quite fragmented due to
                                     the presence of a number of small local players. However, a large number of acquisitions of the
                                     smaller players by the market leaders are resulting in consolidation of the market. For instance,
                                     during 2005-2007, Siemens acquired Diagnostic Products Corporation, Dade Behring, and Bayer
                                     Diagnostics Division. Another leading trend is the entry of diagnostic imaging companies such as
                                     Siemens and Philips into the IVD market.




In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                                          GBIHC064MR / Published JAN 2011
                                                                                                                                              Page 2
                                                                               © GBI Research. This is a licensed product and is not to be photocopied
                                     Rising Emphasis on Patient Centric, Personalized Medicine to Accelerate Development of
                                     Companion Diagnostics
                                     Companion diagnostics involves utilization of biomarkers for new diagnostic tools and to identify a
                                     patient population for a particular drug. It can provide information that is more dynamic, sensitive,
                                     and specific for disease progression in a patient and prescribe drugs which are tailored to the
                                     person’s genetic make-up.
                                     Across the globe, healthcare providers are turning their attention to spiraling healthcare costs due
                                     to the increasing prescriptions of expensive drugs which may or may not work for all individuals.
                                     Moreover, the rise in the mortality due to the adverse drug reactions from inappropriate prescription
                                     drugs has gained interest in the face of tightening budgets. Pharmacogenomics is increasingly
                                     being seen as a solution for administering drugs which work, by assessing the patient’s genetic
                                     disposition for drug metabolism, hence avoiding costs associated with adverse drug reactions.
                                     Many IVD companies are evaluating business models based on molecular diagnostics by
                                     collaborating with pharmaceutical companies for pharmacogenomic testing as the driving force
                                     behind the shift toward personalized medicine.
                                     Companion Diagnostics Hold Tremendous Potential in Personalizing Medicine: Oncology
                                     Will Remain the Prime Focus
                                     The application of advanced technologies for the development of personalized medicine, be it
                                     diagnostics or therapeutics, in the drug discovery process is becoming increasingly evident. The
                                     integration of pharmacogenomic data in clinical trials and drug development process helps in
                                     selecting patients that are more likely to respond or least likely to suffer any side effects. This
                                     considerably reduces the time, size and expense of clinical trials and also helps pharmaceutical
                                     companies to overcome the challenges posed by conventional processes which are time
                                     consuming and expensive. Thus, many pharmaceutical companies are turning towards drug and
                                     diagnostic co-development.
                                     Development of companion diagnostics in oncology is gaining momentum, owing to genetic
                                     variations and Single Nucleotide Polymorphisms (SNPs) involved in cancers and the resulting
                                     genetically defined patient subtypes. A number of therapeutics and biomarkers are focused on
                                     cancer research to allow better understanding of the disease. Within oncology, the major
                                     indications are breast cancer, lung cancer and colorectal cancer. The other major therapeutic areas
                                     of interest to pharmaceutical companies include infectious diseases, immunology and
                                     cardiovascular diseases.




In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                               GBIHC064MR / Published JAN 2011
                                                                                                                                       Page 3
                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                     1         Table of Contents
                                     1 Table of Contents ........................................................................................................................ 4
                                       1.1    List of Tables..................................................................................................................... 8
                                       1.2    List of Figures ................................................................................................................. 10
                                     2 Global IVD and CDx Market: Introduction and Overview........................................................... 12
                                       2.1    In-vitro and Companion diagnostics................................................................................ 12
                                          2.1.1     Overview ................................................................................................................. 12
                                       2.2    GBI Research Report Guidance ..................................................................................... 13
                                     3 Global IVD and CDx Market: Market Characterization .............................................................. 14
                                       3.1    Global IVD and CDx Market, Revenues ($m), 2002–2009 ............................................. 14
                                       3.2    Global IVD and CDx Market, Revenue Forecasts ($m), 2009–2016............................... 16
                                       3.3    Global IVD and CDx Market, Key Company Shares (%), 2009....................................... 18
                                       3.4    Global IVD and CDx Market: Key Market Trends............................................................ 19
                                          3.4.1     Entry of Diagnostic Imaging Players Into In Vitro Diagnostics Market has Set the
                                                    Stage for New Technologies to be Developed by Marrying the Two Disciplines ..... 19
                                          3.4.2     Large Number of Private Equity/Venture Capital (PE/VC) Investments and
                                                    Collaborations in the IVD Sector will Fuel Innovation .............................................. 20
                                          3.4.3     Consolidation of Laboratories across the World ...................................................... 20
                                       3.5    Global IVD and CDx Market: Key Technology Trends .................................................... 21
                                          3.5.1     Emerging Technologies for Cutting Laboratory Costs ............................................. 21
                                          3.5.2     New Technologies Improve Speed and Accuracy ................................................... 22
                                       3.6    Global IVD and CDx Market: Market Drivers................................................................... 23
                                          3.6.1     Economic Market Drivers ........................................................................................ 23
                                          3.6.2     Technology Market Drivers...................................................................................... 25
                                          3.6.3     Regulatory Market Drivers ....................................................................................... 25
                                          3.6.4     Social Market Drivers .............................................................................................. 26
                                       3.7    Global IVD and CDx Market: Market Restraints.............................................................. 26
                                          3.7.1     Economic Market Restraints.................................................................................... 26
                                          3.7.2     Social Market Restraints.......................................................................................... 27
                                     4 Global IVD and CDx Market: Market Category Analysis and Forecasts .................................... 28
                                       4.1    Clinical Chemistry Market: Market Characterization ....................................................... 28
                                          4.1.1     Global Clinical Chemistry Market, Revenues ($m), 2002–2009 .............................. 28
                                          4.1.2     Global Clinical Chemistry Market, Revenue Forecasts ($m), 2009–2016 ............... 30
                                          4.1.3     Global Clinical Chemistry Market, Key Company Shares (%), 2009 ....................... 32
                                          4.1.4     Clinical Chemistry Market: Market Drivers............................................................... 33
                                          4.1.5     Clinical Chemistry Market: Market Restraints .......................................................... 34
                                       4.2    Immuno Chemistry Market: Market Characterization ...................................................... 36
                                          4.2.1     Global Immuno Chemistry Market, Revenues ($m), 2002–2009 ............................. 36
                                          4.2.2     Global Immuno Chemistry Market, Revenue Forecasts ($m), 2009–2016 .............. 38
                                          4.2.3     Global Immuno Chemistry Market, Key Company Shares (%), 2009 ...................... 40
                                          4.2.4     Immuno Chemistry Market: Market Drivers ............................................................. 42
                                          4.2.5     Immuno Chemistry Market: Market Restraints......................................................... 44
                                       4.3    Hematology Market: Market Characterization ................................................................. 45
                                          4.3.1     Global Hematology Market, Revenues ($m), 2002–2009........................................ 45
                                          4.3.2     Global Hematology Market, Revenue Forecasts ($m), 2009–2016 ......................... 47
                                          4.3.3     Global Hematology Market, Key Company Shares (%), 2009................................. 49
                                          4.3.4     Hematology Market: Market Drivers ........................................................................ 50
                                          4.3.5     Hematology Market: Market Restraints ................................................................... 51
                                       4.4    Histology and Cytology Market: Market Characterization ............................................... 52
                                          4.4.1     Global Histology and Cytology Market, Revenue ($m), 2002–2009 ........................ 52
                                          4.4.2     Global Histology and Cytology Market, Revenue Forecasts ($m), 2009–2016 ....... 53
                                          4.4.3     Global Histology and Cytology Market, Key Company Shares (%), 2009 ............... 54
                                          4.4.4     Histology and Cytology Market: Market Drivers....................................................... 55
                                          4.4.5     Histology and Cytology Market: Market Restraints .................................................. 56


In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                                                        GBIHC064MR / Published JAN 2011
                                                                                                                                                                         Page 4
                                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                       4.5    Microbiology Culture Market: Market Characterization ................................................... 57
                                          4.5.1    Global Microbiology Culture Market, Revenues ($m), 2002–2009 .......................... 57
                                          4.5.2    Global Microbiology Culture Market, Revenue Forecasts ($m), 2009–2016 ........... 59
                                          4.5.3    Global Microbiology Culture Market, Key Company Shares (%), 2009 ................... 61
                                          4.5.4    Global Microbiology Culture Market: Market Drivers ............................................... 62
                                          4.5.5    Global Microbiology Culture Market: Market Restraints........................................... 63
                                       4.6    Infectious Immunology Market: Market Characterization ................................................ 64
                                          4.6.1    Global Infectious Immunology Market, Revenues ($m), 2002–2009 ....................... 64
                                          4.6.2    Global Infectious Immunology Market, Revenue Forecasts ($m), 2009–2016 ........ 65
                                          4.6.3    Global Infectious Immunology Market, Key Company Shares (%), 2009 ................ 66
                                          4.6.4    Global Infectious Immunology Market: Market Drivers ............................................ 67
                                          4.6.5    Global Infectious Immunology Market: Market Restraints ....................................... 68
                                       4.7    Genetic Testing Market: Market Characterization ........................................................... 69
                                          4.7.1    Global Genetic Testing Market, Revenues ($m), 2002–2009 .................................. 69
                                          4.7.2    Global Genetic Testing Market, Revenue Forecasts ($m), 2009–2016 ................... 70
                                          4.7.3    Global Genetic Testing Market, Key Company Shares (%), 2009 ........................... 71
                                          4.7.4    Global Genetic Testing Market: Market Drivers ....................................................... 72
                                          4.7.5    Global Genetic Testing Market: Market Restraints .................................................. 73
                                       4.8    Global Companion Diagnostics Market: Market Characterization ................................... 74
                                          4.8.1    Introduction.............................................................................................................. 74
                                          4.8.2    Selected Companion Diagnostic Assays/Kits .......................................................... 77
                                          4.8.3    Applications of Companion Diagnostics .................................................................. 80
                                          4.8.4    Global Companion Diagnostics Market, Revenue Forecasts ($m), 2009–2016 ..... 82
                                          4.8.5    Global Companion Diagnostics Market, Oncology, Revenue Forecasts ($m), 2009-
                                                   2016 ........................................................................................................................ 83
                                          4.8.6    Global Companion Diagnostics Market, Infectious Diseases, Revenue Forecasts
                                                   ($m), 2009-2016 ...................................................................................................... 85
                                          4.8.7    Global Companion Diagnostics Market, Cardiovascular Diseases, Revenue
                                                   Forecasts ($m), 2009-2016 ..................................................................................... 87
                                          4.8.8    Global Companion Diagnostics Market, 2010 ......................................................... 88
                                          4.8.9    Global Companion Diagnostics Market: Market Drivers .......................................... 89
                                          4.8.10 Global Companion Diagnostics Market: Market Restraints ..................................... 89
                                     5 Global IVD and CDx Market: Country Analysis and Forecasts .................................................. 91
                                       5.1    Global IVD Market: Geographic Trends Analysis............................................................ 91
                                       5.2    Market Characterization, the US, 2002–2016 ................................................................. 92
                                          5.2.1    The US IVD and CDx Market, Revenues ($m), 2002–2009 .................................... 92
                                          5.2.2    The US IVD and CDx Market, Revenues ($m), 2009–2016 .................................... 94
                                          5.2.3    The US IVD and CDx Market, Market Drivers ......................................................... 95
                                          5.2.4    The US IVD and CDx Market, Market Restraints..................................................... 95
                                       5.3    Market Characterization, Europe, 2002–2016................................................................. 96
                                          5.3.1    The UK IVD and CDx Market................................................................................... 96
                                          5.3.2    The UK IVD and CDx Market, Revenues ($m), 2009–2016 .................................... 97
                                          5.3.3    Germany IVD and CDx Market, Revenues ($m), 2002–2009.................................. 99
                                          5.3.4    Germany IVD and CDx Market, Revenues ($m), 2009–2016................................ 101
                                          5.3.5    France IVD and CDx Market, Revenues ($m), 2002–2009 ................................... 103
                                          5.3.6    France IVD and CDx Market, Revenues ($m), 2009–2016 ................................... 105
                                          5.3.7    Italy IVD and CDx Market, Revenues ($m), 2002–2009........................................ 107
                                          5.3.8    Italy IVD and CDx Market, Revenues ($m), 2009 – 2016...................................... 109
                                          5.3.9    Spain IVD and CDx Market, Revenues ($m), 2002–2009 ..................................... 111
                                          5.3.10 Spain IVD and CDx Market, Revenues ($m), 2009–2016 ..................................... 113
                                          5.3.11 Europe IVD and CDx Market, Market Drivers ........................................................ 114
                                          5.3.12 Europe IVD and CDx Market, Market Restraints ................................................... 115
                                       5.4    Market Characterization, Japan, 2002–2016 ................................................................ 116
                                          5.4.1    Japan IVD and CDx Market, Revenues ($m), 2002–2009..................................... 116
                                          5.4.2    Japan IVD and CDx Market, Revenues ($m), 2009–2016..................................... 118


In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                                                        GBIHC064MR / Published JAN 2011
                                                                                                                                                                         Page 5
                                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                            5.4.3    Japan IVD and CDx Market, Market Drivers.......................................................... 119
                                            5.4.4    Japan IVD and CDx Market, Market Restraints ..................................................... 120
                                     6   Global IVD and CDx Market: Strategic Competitive Assessment ............................................ 121
                                         6.1    Key Market Participants ................................................................................................ 121
                                            6.1.1    F. Hoffmann-La Roche Ltd .................................................................................... 121
                                            6.1.2    Siemens Medical Solutions USA, Inc. ................................................................... 125
                                            6.1.3    Abbott Laboratories ............................................................................................... 127
                                            6.1.4    Beckman Coulter, Inc. ........................................................................................... 130
                                            6.1.5    bioMerieux Sa........................................................................................................ 133
                                            6.1.6    Ortho-Clinical Diagnostics ..................................................................................... 135
                                            6.1.7    Becton, Dickinson and Company........................................................................... 136
                                            6.1.8    Bio-Rad Laboratories, Inc. ..................................................................................... 138
                                            6.1.9    Roche Diagnostics................................................................................................. 138
                                            6.1.10 Epigenomics AG.................................................................................................... 140
                                            6.1.11 Qiagen N.V ............................................................................................................ 141
                                            6.1.12 Dako Denmark A/S................................................................................................ 142
                                            6.1.13 Celera Corporation ................................................................................................ 143
                                     7   Global IVD and CDx Market: Product Pipeline Analysis .......................................................... 145
                                         7.1    Pipeline Products Analysis by Category ....................................................................... 145
                                            7.1.1    Pipeline Products Analysis: Immuno Chemistry Market ........................................ 146
                                            7.1.2    Pipeline Products Analysis: Infectious Immunology............................................... 148
                                            7.1.3    Pipeline Products Analysis: Companion Diagnostics............................................. 149
                                         7.2    Key Pipeline Products Currently Undergoing Development .......................................... 151
                                            7.2.1    Clinical Chemistry Pipeline Products ..................................................................... 151
                                            7.2.2    Genetic Testing ..................................................................................................... 151
                                            7.2.3    Hematology ........................................................................................................... 152
                                            7.2.4    Immunochemistry .................................................................................................. 152
                                            7.2.5    Infectious Immunology........................................................................................... 153
                                            7.2.6    Microbiology Culture.............................................................................................. 154
                                            7.2.7    Histology and Cytology .......................................................................................... 155
                                            7.2.8    Companion Diagnostics......................................................................................... 155
                                     8   Global IVD and CDx Market: Consolidation Landscape .......................................................... 156
                                         8.1    Deals by Type, 2006–2010 ........................................................................................... 156
                                         8.2    Key M&A Deals, 2009 and 2010 ................................................................................... 157
                                            8.2.1    Merck Completes Acquisition of Millipore .............................................................. 157
                                            8.2.2    Laboratory Corporation of America Completes Acquisition of Genzyme Genetics
                                                     From Genzyme...................................................................................................... 157
                                            8.2.3    GE Healthcare Completes Acquisition of Clarient ................................................. 158
                                            8.2.4    Agilent Technologies Receives Shareholders Approval To Acquire Varian........... 158
                                            8.2.5    Beckman Coulter Completes Acquisition Of Olympus-DS From OLYMPUS ......... 159
                                            8.2.6    MDS Receives Shareholder Approval To Sell MDS Analytical Technologies To
                                                     Danaher................................................................................................................. 159
                                     9   Appendix ................................................................................................................................. 165
                                         9.1    Market Definitions ......................................................................................................... 165
                                            9.1.1    Clinical Chemistry.................................................................................................. 165
                                            9.1.2    Immunochemistry Test Reagents .......................................................................... 166
                                            9.1.3    Hematology ........................................................................................................... 167
                                            9.1.4    Histology and Cytology .......................................................................................... 168
                                            9.1.5    Microbiology Culture.............................................................................................. 169
                                            9.1.6    Infectious Immunology........................................................................................... 169
                                            9.1.7    Genetic Testing ..................................................................................................... 170
                                            9.1.8    Acquired Gene or Chromosome Alterations .......................................................... 170
                                            9.1.9    Companion Diagnostics......................................................................................... 170
                                         9.2    List of Abbreviations...................................................................................................... 171
                                         9.3    Research Methodology ................................................................................................. 172


In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                                                           GBIHC064MR / Published JAN 2011
                                                                                                                                                                             Page 6
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                            9.3.1    Secondary Research ............................................................................................. 172
                                            9.3.2    Primary Research.................................................................................................. 172
                                            9.3.3    Models ................................................................................................................... 173
                                            9.3.4    Forecasts............................................................................................................... 173
                                            9.3.5    Expert Panels ........................................................................................................ 173
                                         9.4    Contact Us .................................................................................................................... 174
                                         9.5    Disclaimer ..................................................................................................................... 174
                                         9.6    Sources......................................................................................................................... 174




In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                                                         GBIHC064MR / Published JAN 2011
                                                                                                                                                                          Page 7
                                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                     1.1     List of Tables
                                     Table 1:    IVD and CDx Market, Global, Revenue ($m), 2002-2009 .............................................. 14
                                     Table 2:    IVD and CDx Market, Global, Revenue ($m), 2009-2016 .............................................. 16
                                     Table 3:    IVD Market, Global, Company Revenues ($m), 2009 .................................................... 18
                                     Table 4:    Clinical Chemistry Market, Global, Revenues ($m), 2002–2009 .................................... 28
                                     Table 5:    Clinical Chemistry Market, Global, Revenue ($m), 2009–2016...................................... 30
                                     Table 6:    Clinical Chemistry Market, Global, Company Revenues ($m), 2009.............................. 32
                                     Table 7:    Clinical Chemistry Market, Comparison of Top Seven Countries by Revenue, 2002–
                                                 2016 ...............................................................................................................................33
                                     Table 8:    Immuno Chemistry Market, Global, Revenues ($m), 2002–2009................................... 36
                                     Table 9:    Immuno Chemistry Market, Global, Revenue ($m), 2009–2016 .................................... 38
                                     Table 10:   Immuno Chemistry Market, Global, Company Revenues ($m), 2009 ............................ 40
                                     Table 11:   Immuno Chemistry Market, Comparison of Top Seven Countries by Revenue, 2002–
                                                 2016 ...............................................................................................................................42
                                     Table 12:   Hematology Market, Global, Revenue ($m), 2002–2009 ............................................... 45
                                     Table 13:   Hematology Market, Global, Revenue ($m), 2009–2016 ............................................... 47
                                     Table 14:   Hematology Market, Global, Company Revenues ($m), 2009 ....................................... 49
                                     Table 15:   Hematology Market, Comparison of Top Seven Countries by Revenue, 2002–2016 .... 50
                                     Table 16:   Histology and Cytology Market, Global, Revenue ($m), 2002-2009............................... 52
                                     Table 17:   Histology and Cytology Market, Global, Revenue ($m), 2009–2016.............................. 53
                                     Table 18:   Histology and Cytology Market, Global, Company Revenues ($m), 2009...................... 54
                                     Table 19:   Histology and Cytology Market, Comparison of Top Seven Countries by Revenue,
                                                 2002–2016 ..................................................................................................................... 55
                                     Table 20:   Microbiology Culture Market, Global, Revenue ($m), 2002–2009.................................. 57
                                     Table 21:   Microbiology Culture Market, Global, Revenue ($m), 2009–2016.................................. 59
                                     Table 22:   Microbiology Culture Market, Global, Company Revenues ($m), 2009.......................... 61
                                     Table 23:   Microbiology Culture Market, Comparison of Top Seven Countries by Revenue ($m),
                                                 2002–2016 ..................................................................................................................... 62
                                     Table 24:   Infectious Immunology Market, Global, Revenue ($m), 2002–2009............................... 64
                                     Table 25:   Infectious Immunology Market, Global, Revenue ($m), 2009–2016............................... 65
                                     Table 26:   Infectious Immunology Market, Global, Company Revenues ($m), 2009 ...................... 66
                                     Table 27:   Infectious Immunology Market, Comparison of Top Seven Countries by Revenue ($m),
                                                 2002–2016 ..................................................................................................................... 67
                                     Table 28:   Genetic Testing Market, Global, Revenue ($m), 2002–2009 ......................................... 69
                                     Table 29:   Genetic Testing Market, Global, Revenue ($m), 2009–2016 ......................................... 70
                                     Table 30:   Global Genetic Testing Market, Global, Company Revenues ($m), 2009...................... 71
                                     Table 31:   Genetic Testing Market, Comparison of Top Seven Countries by Revenue ($m), 2002–
                                                 2016 ...............................................................................................................................72
                                     Table 32:   Companion Diagnostics, List of Selected Companion Diagnostics and Personalized
                                                 Therapeutics, 2010* ....................................................................................................... 76
                                     Table 33:   Companion Diagnostics Market, Oncology, Global, Revenues ($m), 2009–2016.......... 83
                                     Table 34:   Global Companion Diagnostics Market, Infectious Diseases, 2010 ............................... 86
                                     Table 35:   Companion Diagnostics Market, Cardiovascular, the US, Revenues ($m), 2009–2016 87
                                     Table 36:   IVD and CDx Market, the US, Revenue ($m), 2002-2009.............................................. 92
                                     Table 37:   IVD and Companion Diagnostics Market, the US, Revenue ($m), 2009-2016............... 94
                                     Table 38:   IVD and CDx Market, The UK, Revenue ($m), 2002-2009 ............................................ 96
                                     Table 39:   IVD Market, The UK, Revenue ($m), 2009-2016 ........................................................... 97
                                     Table 40:   IVD Market, Germany, Revenues ($m), 2002–2009 ...................................................... 99
                                     Table 41:   IVD Market, Germany, Revenue ($m), 2009-2016....................................................... 101
                                     Table 42:   IVD Market, France, Revenue ($m), 2002-2009 .......................................................... 103
                                     Table 43:   IVD Market, France, Revenue ($m), 2009-2016 .......................................................... 105
                                     Table 44:   IVD and CDx Market, Italy, Revenue ($m), 2002-2009 ................................................ 107
                                     Table 45:   IVD Market, Italy, Revenue ($m), 2009-2016 ............................................................... 109
                                     Table 46:   IVD Market, Spain, Revenue ($m), 2002-2009 ............................................................ 111
                                     Table 47:   IVD and CDx Market, Spain, Revenue ($m), 2009-2016 ............................................. 113
                                     Table 48:   IVD Market, Japan, Revenue ($m), 2002-2009............................................................ 116
                                     Table 49:   IVD and CDx Market, Japan, Revenue ($m), 2009-2016............................................. 118
                                     Table 50:   Roche’s Merger and Acquisitions, IVD Market, 2007–2009 ......................................... 122
                                     Table 51:   Roche IVD Pipeline Product Portfolio........................................................................... 123
                                     Table 52:   Siemen’s Merger and Acquisitions, IVD Market, 2007–2009 ....................................... 125
                                     Table 53:   Siemens Medical Solutions IVD Pipeline Product Portfolio .......................................... 126
                                     Table 54:   Abbott Laboratories’ Mergers and Acquisitions, IVD Market, 2007–2009 .................... 128

In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                                                          GBIHC064MR / Published JAN 2011
                                                                                                                                                                             Page 8
                                                                                     © GBI Research. This is a licensed product and is not to be photocopied
                                     Table 55:   Abbott Laboratories’ Licensing Deals, Companion Diagnostics Market, 2004–2010 ... 128
                                     Table 56:   Abbott Laboratories IVD Pipeline Products .................................................................. 129
                                     Table 57:   Abbott Diagnostics, Companion Diagnostics Pipeline Portfolio.................................... 130
                                     Table 58:   Beckman Coulter’s Mergers and Acquisitions, IVD Market, 2007–2009 ...................... 131
                                     Table 59:   Beckman Coulter, Inc. IVD Pipeline Products .............................................................. 132
                                     Table 60:   bioMerieux’s Mergers and Acquisitions, IVD Market, 2007–2009 ................................ 134
                                     Table 61:   bioMerieux’s Mergers and Acquisitions, Companion Diagnostics Market, 2004–2010134
                                     Table 62:   bioMerieux Sa IVD Pipeline Products .......................................................................... 135
                                     Table 63:   bioMerieux, Inc., Companion Diagnostics Pipeline Portfolio ........................................ 135
                                     Table 64:   Ortho-Clinical Diagnostics, IVD Pipeline Products ....................................................... 136
                                     Table 65:   Becton Dickinson, Mergers and Acquisitions, IVD Market, 2007–2009........................ 137
                                     Table 66:   Becton, Dickinson Inc. IVD Pipeline Portfolio ............................................................... 137
                                     Table 67:   Bio-Rad Laboratories, Merger and Acquisitions, IVD Market, 2007–2009 ................... 138
                                     Table 68:   Roche Diagnostics, Licensing Deals, Companion Diagnostics Market, 2004–2010 .... 139
                                     Table 69:   Roche Diagnostics, Companion Diagnostics Pipeline Portfolio, 2010.......................... 140
                                     Table 70:   Epigenomics, Companion Diagnostics, Licensing Deals, 2004-2010........................... 141
                                     Table 71:   Epigenomics, Companion Diagnostics Pipeline Portfolio, 2010 ................................... 141
                                     Table 72:   Qiagen N.V, Licensing Deals, Companion Diagnostics Market, 2004–2010................ 142
                                     Table 73:   Qiagen, Companion Diagnostics Pipeline Portfolio, 2010 ............................................ 142
                                     Table 74:   Dako Denmark A/S, Licensing Deals, Companion Diagnostics Market, 2004–2010.... 143
                                     Table 75:   Dako Denmark A/S, Companion Diagnostics Pipeline Portfolio, 2010 ......................... 143
                                     Table 76:   Celera, Licensing Deals, 2004-2010 ............................................................................ 144
                                     Table 77:   Celera, Companion Diagnostics Pipeline Portfolio ....................................................... 144
                                     Table 78:   IVD and CDx Market, Global, Pipeline Products by Category, 2010 ............................ 145
                                     Table 79:   Immuno Chemistry Market, Global, Pipeline Products Analysis, 2010......................... 146
                                     Table 80:   Infectious Immunology Market, Global, 2010 ............................................................... 148
                                     Table 81:   Deals By Type, Global IVD and CDx Market, 2006-2010............................................. 156
                                     Table 82:   Key Deals, Mergers and Acquisitions, Global IVD Market, 2010.................................. 160
                                     Table 83:   Key Deals, Mergers and Acquisitions, Global IVD Market, 2009.................................. 162




In-vitro and Companion Diagnostics Industry - 2010 Yearbook                                                              GBIHC064MR / Published JAN 2011
                                                                                                                                                           Page 9
                                                                                © GBI Research. This is a licensed product and is not to be photocopied
                                     1.2     List of Figures
				
DOCUMENT INFO
Description: In-vitro and Companion Diagnostics Industry - 2010 Yearbook Summary GBI Research’s report, “In-vitro and Companion Diagnostics Industry- 2010 Yearbook” provides key data, information and analysis on the global invitro diagnostic and companion diagnostics market. The report provides a market landscape, competitive landscape and market trends information on the following market categories: clinical chemistry, immunochemistry, hematology, histology and cytology, microbiology, infectious immunology, genetic testing and companion diagnostics. The report provides comprehensive information on the key trends affecting the aforementioned categories, and key analytical content on the market dynamics. The report also reviews the latest, advances in in-vitro diagnostics technology. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope Its scope includes: - Market revenue data from 2002 to 2009. Forecast revenue data to 2016. Company shares data for 2009. - Market size and company share data for six diagnostic imaging market categories: clinical chemistry, immunochemistry, hematology, histology and cytology, microbiology, infectious immunology, genetic testing and companion diagnostics. - Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain and Japan. - Qualitative analysis of the key market trends, and market drivers and restraints, by each category within the diagnostic imaging market. - The report also covers information on the leading market players, the competitive landscape, and the leading technologies. - Key players covered include F.Hoffman-La Roche, Abbott Laboratories, bioMerieux, Beckman Coulter, Qiagen, Dako Denmark A/S, Siemens Medical Solutions. Reasons to buy The report will enhance your decision making capability. It will allow you to: - Develop business strategies by u
BUY THIS DOCUMENT NOW PRICE: $3500 100% MONEY BACK GUARANTEED
PARTNER GBI Research
GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.